We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock

Delisted

NBSE was delisted on the 10th of May, 2024.

52 hedge funds and large institutions have $43.1M invested in NeuBase Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more call options, than puts

Call options by funds: $1.94M | Put options by funds: $1.03M

80% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 10

9% less funds holding

Funds holding: 5752 (-5)

23% less capital invested

Capital invested by funds: $55.8M → $43.1M (-$12.8M)

45% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 11

Holders
52
Holders Change
-5
Holders Change %
-8.77%
% of All Funds
1.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
18
Reduced
10
Closed
11
Calls
$1.94M
Puts
$1.03M
Net Calls
+$909K
Net Calls Change
+$3.83M

NBSE Hedge Fund Activity: Q3 2014 in Review

52 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2014, worth a combined $43.1M — down 23% from $55.8M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of NBSE and 6 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 18 added.

The largest buyer was Northern Trust, adding an estimated $1.34M. The largest seller was Millennium Management, cutting an estimated $1.35M.

  • 52 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2014, down from 57 in Q2 2014.
  • Funds reported $43.1M of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2014, down 23% quarter-over-quarter.
  • 6 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2014 and 11 closed out, a net change of -5 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q3 2014 was Northern Trust, an estimated $1.34M added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2014 was Millennium Management, an estimated $1.35M sold.

Based on aggregated 13F filings for Q3 2014.